Safety of Emergent Intracranial Stenting after Thrombolysis: A Multicenter Matched Analysis.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Alexandre Andrea M, Scarcia Luca, Consoli Arturo, Sun Wen, Xu Yingjie, Huang Xianjun, Chung Charlotte, Sgreccia Alessandro, Abdalkader Mohamad, Limbucci Nicola, Pedicelli Alessandro, De Leoni Davide, Ganimede Maria P, Gaudino Chiara, Russo Riccardo, Papagiannaki Chrysanthi, Partesano Roberta, Mandruzzato Nicolò, Gabrieli Joseph D, Panni Pietro, Zini Andrea, Clarençon Frédéric, Raz Eytan, Nguyen Thanh N, Broccolini Aldobrando, collaborators of the emergent Intra-Cranial Artery Stenting (eICAS) International Study Group, Collaborators of the emergent Intra-Cranial Arterial Stenting (eICAS) international study group
Аннотация
MATERIALS AND METHODS: We screened the prospective databases of 26 stroke centers across Europe, the United States, and China for consecutive patients with acute MCA ICAS-LVO who received RS. Patients were divided into 2 groups based on prior administration of IVT: IVT/RS and no-IVT/RS. Propensity score matching (PSM), based on a set of covariates that also included periprocedural antiplatelet therapies, was used to estimate the effect of IVT treatment. Primary safety outcomes were the occurrence of symptomatic intracranial hemorrhage (sICH) and 90-day mortality.
RESULTS: After PSM, 52 pairs of patients were available for analysis. No significant differences were observed between the 2 groups regarding rates of sICH (11.5% in IVT/RS group versus 9.6% in no-IVT/RS group; OR = 1.2; 95% CI, 0.4-4.3; P = .75) and 90-day mortality (14.3% in the IVT/RS group versus 11.7% in the no-IVT/RS group; OR = 1.3; 95% CI, 0.4-4.2; P = .71). There were also no significant differences in the occurrence of parenchymal hemorrhage types 1 and 2, successful recanalization rates, and 90-day functional outcome.
CONCLUSIONS: The safety of RS in ICAS-LVO is not significantly affected by prior IVT administration. Furthermore, IVT does not result in improved recanalization and clinical outcome. These findings should be interpreted with caution and require validation through future randomized controlled studies.